首页> 美国卫生研究院文献>Springer Open Choice >A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis

【2h】

A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis

机译：一项为期44周的开放标签研究评估局部用甲苯磺酸格列罗铵在原发性腋窝多汗症患者中的安全性和有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundGlycopyrronium tosylate is a topical anticholinergic approved in the USA for primary axillary hyperhidrosis in patients aged ≥ 9 years (Qbrexza™ [glycopyrronium] cloth, 2.4%).

机译：背景甲苯磺酸格隆铵是在美国被批准用于≥9岁患者的原发性腋窝多汗症的局部抗胆碱能药物（Qbrexza™[glycopyrronium]布，2.4％）。

著录项

期刊名称 Springer Open Choice
作者
Dee Anna Glaser; Adelaide A. Hebert; Alexander Nast; William P. Werschler; Lawrence Green; Richard D. Mamelok; John Quiring; Janice Drew; David M. Pariser;
展开▼
作者单位

展开▼
年(卷),期 -1(20),4
年度 -1
页码 593–604
总页数 12
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis [J] . Glaser Dee Anna, Hebert Adelaide A., Nast Alexander, American journal of clinical dermatology . 2019,第4期

机译：一个44周的开放标签研究评估局部腋窝瘤患者局部甘油酮甲磺酸盐的安全性和疗效
2. Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study [J] . Pediatric dermatology . 2020,第3期

机译：用于治疗原发性腋窝瘤的局部糖类甘油苷的长期疗效和安全性：HOC儿科亚组分析来自44周的开放标签扩展研究
3. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double‐blind, placebo‐controlled study [J] . Masur C., Soeberdt M., Kilic A., British Journal of Dermatology . 2020,第1期

机译：含有0·5,1和2％糖酮溴铵的局部制剂的安全性和有效性，初级腋窝血管症患者：随机，双盲，安慰剂对照研究
4. Skin AC conductance levels and responses in axillary hyperhidrosis patients [C] . C. Tronstad, A.L. Krogstad, H. Kalvoy, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：腋窝多汗症患者的皮肤AC电导水平和反应
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials [O] . Adelaide A. Hebert, Dee Anna Glaser, Lawrence Green, -1

机译：小儿原发性腋窝多汗症中的甲苯磺酸格隆铵：根据两项三期随机对照试验按年龄对疗效和安全性结果进行事后分析
7. Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study [O] . Adelaide A. Hebert, Dee Anna Glaser, Lawrence Green, 2020

机译：用于治疗原发性腋窝瘤的局部糖酮甲酸酯的长期疗效和安全性：44周开放标签扩展研究中的HOC儿科亚组分析

A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis

摘要

著录项

相似文献

相关主题

期刊订阅